- Conditions
- Extreme Immaturity
- Interventions
- Sodium chloride, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 7 Days to 8 Days
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 212
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Determine the Effects of Nitrosigine and Citrulline-malate on Flow-mediated Dilation Among Young Adults
- Interventions
- inositol-stabilized arginine silicate
- Dietary Supplement
- Lead sponsor
- University of Arkansas, Fayetteville
- Other
- Eligibility
- 18 Years to 29 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Fayetteville, Arkansas
- Conditions
- Type 2 Diabetes
- Interventions
- HM11260C, liraglutide, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- CA, California
- Conditions
- Congenital Diaphragmatic Hernia, Persistent Pulmonary Hypertension of the Newborn, Hypoxemic Respiratory Failure, Pulmonary Hypoplasia
- Interventions
- Milrinone, Placebo (5% Dextrose)
- Drug
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- 0 Hours to 168 Hours
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 15 more
- Conditions
- Bacterial Infections
- Interventions
- Xeruborbactam, Cefiderocol, Xeruborbactam/Cefiderocol, Dextrose 5% in water
- Drug
- Lead sponsor
- Qpex Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Congenital Cytomegalovirus Infection, Maternal Cytomegalovirus Infection
- Interventions
- CMV hyperimmune globulin, Placebo
- Drug · Other
- Lead sponsor
- The George Washington University Biostatistics Center
- Other
- Eligibility
- Female only
- Enrollment
- 399 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2021
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more
- Conditions
- Type 2 Diabetes
- Interventions
- Placebo, Insulin Glargine 0.5 u/kg body wt SC, Insulin Glargine 1.0 u/kg body wt SC, Insulin Glargine 1.5 u/kg body wt SC, Insulin Glargine 2.0 u/kg body wt SC
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Asthma
- Interventions
- QBX258, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 15
- States / cities
- Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more
- Conditions
- Cerebral Palsy
- Interventions
- Cord Blood Infusion, Intravenous Sham
- Biological
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 1 Year to 12 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Reperfusion Injury
- Interventions
- Ascorbic Acid, 5 % Dextrose Water or Normal Saline
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Thyroid Goiter, Hypothyroidism, Thyroid Cancer
- Interventions
- Levothyroxine, Liothyronine, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
- Biological · Other · Procedure
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Alcoholic Hepatitis, Sepsis
- Interventions
- Vitamin C, Dextrose 5% in water
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Impaired Glucose Tolerance
- Interventions
- Saxagliptin, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Coronary Artery Disease
- Interventions
- Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Crohn's Disease
- Interventions
- abatacept, placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 451 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Portal Hypertension, Liver Cirrhosis
- Interventions
- Ifetroban, Placebo
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
- Conditions
- Critically Ill, Respiratory Failure
- Interventions
- Thiamine
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Canakinumab, Metformin, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 556 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
- Conditions
- Metabolic Syndrome
- Interventions
- intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test
- Procedure · Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 50 Years to 75 Years · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- TNBC - Triple-Negative Breast Cancer, Breast Cancer
- Interventions
- Trilaciclib, Placebo, Gemcitabine, Carboplatin
- Drug
- Lead sponsor
- G1 Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more
- Conditions
- Type II Diabetes
- Interventions
- Placebo, Sitagliptin, LEZ763
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more